Analysis of Expression in Multiple Sclerosis Patients

Overview

Journal Rep Biochem Mol Biol

Specialty Biochemistry

Date 2020 Jun 26

PMID 32582802

Citations 5

Authors

Atefeh Sohan Forooshan Moghadam

Mitra Ataei

Ghazaleh Arabzadeh

Kowsar Falahati

Fatemeh Roshani

Mohammad Hossein Sanati

Affiliations

Soon will be listed here.

Abstract

Background: In multiple sclerosis (MS), the immune system acts against myelin lesions of the central nervous system, destroying neuronal fibers resulting in signal transmission disturbances in the nervous system. MicroRNAs play important roles in the post-transcriptional regulation of gene expression and in the regulation of disease activity and its response to treatment. The goal of this study was to determine the role of by comparing its expression in MS patients and healthy subjects.

Methods: RNA was isolated from blood samples of 32 MS patients and 32 healthy individuals, and miR-18a-5p expression was determined by real-time polymerase chain reaction (real-time PCR).

Results: expression was significantly less in MS patients than in healthy subjects.

Conclusion: The reduction of expression may be via pathway signaling. Altered signaling plays an important role in MS pathogenesis and the expression profile in blood cells can be described as a prognostic biomarker and identifier of high-risk individuals in MS.

Citing Articles

Multiple Sclerosis: Roles of miRNA, lcnRNA, and circRNA and Their Implications in Cellular Pathways.

Cipriano G, Schepici G, Mazzon E, Anchesi I Int J Mol Sci. 2024; 25(4).

PMID: 38396932 PMC: 10889752. DOI: 10.3390/ijms25042255.

Risk Factors from Pregnancy to Adulthood in Multiple Sclerosis Outcome.

Gonzalez-Madrid E, Rangel-Ramirez M, Mendoza-Leon M, Alvarez-Mardones O, Gonzalez P, Kalergis A Int J Mol Sci. 2022; 23(13).

PMID: 35806081 PMC: 9266360. DOI: 10.3390/ijms23137080.

A Significant Reduction in the Plasma Levels and Gene Expression of CCL2 in Patients with Osteoarthritis following Intervention with Krocina™.

Beiki S, Tavakkol-Afshari J, Shariati-Sarabi Z, Poursamimi J, Shabgah A, Mohammadi M Rep Biochem Mol Biol. 2022; 11(1):10-19.

PMID: 35765531 PMC: 9208552. DOI: 10.52547/rbmb.11.1.10.

Correlation of -475 IL-2 Promoter Gene Polymorphisms and the Levels of Serum IL-2 on the Risk of Multiple Sclerosis.

Abdulaali Abed T, Abdulla A Rep Biochem Mol Biol. 2022; 11(1):83-88.

PMID: 35765522 PMC: 9208566. DOI: 10.52547/rbmb.11.1.83.

MicroRNA Alteration, Application as Biomarkers, and Therapeutic Approaches in Neurodegenerative Diseases.

Nguyen T, Kumar M, Fedele E, Bonanno G, Bonifacino T Int J Mol Sci. 2022; 23(9).

PMID: 35563107 PMC: 9104163. DOI: 10.3390/ijms23094718.

References

Montoya M, Maul J, Singh P, Pua H, Dahlstrom F, Wu N . A Distinct Inhibitory Function for miR-18a in Th17 Cell Differentiation. J Immunol. 2017; 199(2):559-569. PMC: 5508756. DOI: 10.4049/jimmunol.1700170. View

Rodriguez A, Vigorito E, Clare S, Warren M, Couttet P, Soond D . Requirement of bic/microRNA-155 for normal immune function. Science. 2007; 316(5824):608-11. PMC: 2610435. DOI: 10.1126/science.1139253. View

Dai R, Ahmed S . MicroRNA, a new paradigm for understanding immunoregulation, inflammation, and autoimmune diseases. Transl Res. 2011; 157(4):163-79. PMC: 3072681. DOI: 10.1016/j.trsl.2011.01.007. View

Huang Q, Xiao B, Ma X, Qu M, Li Y, Nagarkatti P . MicroRNAs associated with the pathogenesis of multiple sclerosis. J Neuroimmunol. 2016; 295-296:148-61. DOI: 10.1016/j.jneuroim.2016.04.014. View

Inglese M . Multiple sclerosis: new insights and trends. AJNR Am J Neuroradiol. 2006; 27(5):954-7. PMC: 7975738. View

Sharief M, Semra Y . Down-regulation of survivin expression in T lymphocytes after interferon beta-1a treatment in patients with multiple sclerosis. Arch Neurol. 2002; 59(7):1115-21. DOI: 10.1001/archneur.59.7.1115. View

Dorn 2nd G . MicroRNAs in cardiac disease. Transl Res. 2011; 157(4):226-35. PMC: 3070425. DOI: 10.1016/j.trsl.2010.12.013. View

Ingwersen J, Menge T, Wingerath B, Kaya D, Graf J, Prozorovski T . Natalizumab restores aberrant miRNA expression profile in multiple sclerosis and reveals a critical role for miR-20b. Ann Clin Transl Neurol. 2015; 2(1):43-55. PMC: 4301674. DOI: 10.1002/acn3.152. View

Junker A, Krumbholz M, Eisele S, Mohan H, Augstein F, Bittner R . MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47. Brain. 2009; 132(Pt 12):3342-52. DOI: 10.1093/brain/awp300. View

10.

Krone B, Grange J . Multiple sclerosis: are protective immune mechanisms compromised by a complex infectious background?. Autoimmune Dis. 2011; 2011:708750. PMC: 3010623. DOI: 10.4061/2011/708750. View

11.

Bizzoco E, Lolli F, Repice A, Hakiki B, Falcini M, Barilaro A . Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution. J Neurol. 2009; 256(11):1891-8. DOI: 10.1007/s00415-009-5171-x. View

12.

Popko B, Corbin J, Baerwald K, Dupree J, Garcia A . The effects of interferon-gamma on the central nervous system. Mol Neurobiol. 1997; 14(1-2):19-35. PMC: 7091409. DOI: 10.1007/BF02740619. View

13.

Milo R, Kahana E . Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmun Rev. 2009; 9(5):A387-94. DOI: 10.1016/j.autrev.2009.11.010. View

14.

Trabattoni D, Saresella M, Pacei M, Marventano I, Mendozzi L, Rovaris M . Costimulatory pathways in multiple sclerosis: distinctive expression of PD-1 and PD-L1 in patients with different patterns of disease. J Immunol. 2009; 183(8):4984-93. DOI: 10.4049/jimmunol.0901038. View

15.

Kozomara A, Griffiths-Jones S . miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res. 2013; 42(Database issue):D68-73. PMC: 3965103. DOI: 10.1093/nar/gkt1181. View

16.

Eftekharian M, Noroozi R, Sayad A, Sarrafzadeh S, Toghi M, Azimi T . RAR-related orphan receptor A (RORA): A new susceptibility gene for multiple sclerosis. J Neurol Sci. 2016; 369:259-262. DOI: 10.1016/j.jns.2016.08.045. View

17.

Kacperska M, Walenczak J, Tomasik B . Plasmatic microRNA as Potential Biomarkers of Multiple Sclerosis: Literature Review. Adv Clin Exp Med. 2016; 25(4):775-9. DOI: 10.17219/acem/60098. View

18.

Lindberg R, Hoffmann F, Mehling M, Kuhle J, Kappos L . Altered expression of miR-17-5p in CD4+ lymphocytes of relapsing-remitting multiple sclerosis patients. Eur J Immunol. 2010; 40(3):888-98. DOI: 10.1002/eji.200940032. View

19.

Gourraud P, Harbo H, Hauser S, Baranzini S . The genetics of multiple sclerosis: an up-to-date review. Immunol Rev. 2012; 248(1):87-103. PMC: 5967887. DOI: 10.1111/j.1600-065X.2012.01134.x. View

20.

Gandhi R, Healy B, Gholipour T, Egorova S, Musallam A, Hussain M . Circulating microRNAs as biomarkers for disease staging in multiple sclerosis. Ann Neurol. 2013; 73(6):729-40. DOI: 10.1002/ana.23880. View